磷酸奥司他韦治疗成人住院流感临床疗效影响因素的分析

中国药物评价 ›› 2022, Vol. 39 ›› Issue (2): 167-171.

磷酸奥司他韦治疗成人住院流感临床疗效影响因素的分析

杨焕芝¹，徐磊²，肖琳³，宋沧桑^1*

1.昆明市第一人民医院药学部，云南昆明 650034;
2.大理大学药学院，云南大理 671000; 3.昆明医科大学药学院，云南昆明 650500

收稿日期:2022-01-28 修回日期:2022-02-10 出版日期:2022-04-28 发布日期:2022-04-28
基金资助:
昆明市卫健委局级卫生科研项目(2020-13-01-113)；云南省卫生健康委员会医学领军人才项目(L-2018012)；昆明市卫生科技人才培养项目(项目编号：2020-SW(省)-13)

Analysis of Factors Influencing the Clinical Efficacy of Oseltamivir Phosphate in the Treatment of Hospitalized Adult Influenza

yang huanzhi,Sang CangSONG

1.Department of Pharmacy, Kuming Municipal First People′s Hospital, Yunnan Kunming 650034, China;
2.College of Pharmaceutical Science, Dali University, Yunnan Dali 671000，China; 3.College of Pharmacy, Kunming Medical University, Yunnan Kunming 650500, China

Received:2022-01-28 Revised:2022-02-10 Online:2022-04-28 Published:2022-04-28
Contact: Sang CangSONG E-mail:songcs163@163.com

摘要/Abstract

摘要：

目的：分析磷酸奥司他韦影响成人流行性感冒(流感)预后的影响因素，旨在为临床用药提供参考。方法：本研究采用回顾性研究方法，通过收集某院2017年1月1日至2019年12月31日呼吸与危重症医学科确诊为流感且使用奥司他韦治疗的成人住院患者病历资料。根据患者症状、体征、实验室检查及病原学结果等信息，分析奥司他韦治疗成人住院流感临床疗效的影响因素。结果：根据纳入及排除标准筛选病例最终入组103例，其中有效组83例，无效组为20例。对有效与无效组相关指标进行单因素分析，结果显示发热、重症肺炎、超敏C反应蛋白、白介素-6、天门冬氨酸氨基转移酶、丙氨酸氨基转移酶以及白蛋白初始指标是奥司他韦治疗成人流感临床疗效的影响因素(P＜0.05)。将单因素有统计学意义的变量纳入Logistic回归分析，结果显示超敏C反应蛋白和重症肺炎是影响奥司他韦疗效的危险因素(P＜0.05)。结论：超敏C反应蛋白升高、合并重症肺炎可能是奥司他韦影响成人住院流感患者预后的因素，临床医师应加强关注。

关键词: 奥司他韦, 流行性感冒, 临床疗效

Abstract:

Objective：This study aimed to analyze the influencing factors of oseltamivir phosphate on prognosis of adult influenza (influenza) and to provide reference for clinical medication. Methods: A retrospective study was conducted to collect medical records of hospitalized adult patients diagnosed with influenza and treated with oseltamivir phosphate from the department of respiratory and Critical Care in a hospital from January 1, 2017 to December 31, 2019. To analyze the factors influencing the clinical efficacy of oseltamivir in the treatment of hospitalized adult influenza according to the information of symptoms, signs, laboratory examination and examination.Results：103 cases were selected according to inclusion and exclusion criteria, including 83 cases in the effective group and 20 cases in the invalid group. Single factor analysis of related indexes in the effective and ineffective groups showed that fever, severe pneumonia, hypersensitive C-reactive protein，interleukin-6，aspartate aminotransferase, alanine aminotransferase and initial albumin indexes were the influencing factors for the efficacy of oseltamivir in the treatment of adult influenza(P<0.05). When univariate variables with statistical significance were included in Logistic regression analysis, the results showed that hypersensitive C-reactive protein and severe pneumonia were risk factors affecting the efficacy of oseltamivir(P＜0.05). Conclusion：The elevation of hypersensitive C-reactive protein and severe pneumonia may be the prognostic factors of oseltamivir in hospitalized adult influenza patients, clinicians should pay more attention to it.

Key words: Oseltamivir, Influenza, Clinical effects

中图分类号:

R978.7

杨焕芝, 徐磊, 肖琳, 宋沧桑.

磷酸奥司他韦治疗成人住院流感临床疗效影响因素的分析 [J]. 中国药物评价, 2022, 39(2): 167-171.

YANG Huan-zhi, XU Lei, XIAO Lin, SONG Cang-sang.

Analysis of Factors Influencing the Clinical Efficacy of Oseltamivir Phosphate in the Treatment of Hospitalized Adult Influenza [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(2): 167-171.

参考文献

[1] 国家卫生健康委员会，国家中医药管理局.流行性感冒诊疗方案(2020年版)[J].中华临床感染病杂志，2020，13(6)：401-405，411.

[2] 容志欢，张博，李鑫，等.改进的LC-MS/MS法同时测定人血浆中奥司他韦及其活性代谢产物浓度[J].中国临床药理学杂志，2021，37(11)：1425-1429.

[3] 王业明，曹彬.抗流感病毒药物的回顾、现状和展望[J].中华流行病学杂志，2018，39(8)：1051-1059.

[4] 曹喜连.磷酸奥司他韦颗粒治疗儿童流感病毒感染的疗效及安全性分析[J].医学理论与实践，2021，34(3)：474-475.

[5] 国家卫生健康委员会，国家中医药局.流行性感冒诊疗方案(2019年版)[J].中华临床感染病杂志，2019，12(6)：451-455.

[6] 周敏.奥司他韦治疗疑似流感的临床疗效及其安全性[J].临床合理用药杂志，2021，14(3)：133-134.

[7] 陈芸，付惠玲，汪宇.甲型、乙型流行性感冒患儿口服磷酸奥司他韦的治疗效果对比观察[J].山东医药，2020，60(30)：84-86.

[8] Nakamura S, Miyazaki T, Izumikawa K, et al.Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study[J]. Open forum infectious diseases，2017，4(3): 129.

[9] 李侗曾，蔡妙甜，张美，等.流行性感冒老年患者的临床特点及预后影响因素[J].中国感染与化疗杂志，2020，20(4)：362-367.

[10] Pepys MB, Hirschfield GM. C-reactive protein: a critical update[J]. J Clin Invest，2003，111(12)：1805-1812.

[11] Bray C, Bell LN, Liang H, et al. Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine[J]. WMJ: official publication of the State Medical Society of Wisconsin，2016，115(6)：317-321.

[12] Harbin NJ，Rystedt K，Lindbaek M, et al. Does C-reactive protein predict time to recovery and benefit from oseltamivir treatment in primary care patients with influenza-like illness? A randomized controlled trial secondary analysis[J].Scand J Prim Health Care，2021，39(4): 527-532.

[13] Hernu R, Chroboczek T, Madelaine T, et al. Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis[J]. Intensive care medicine，2018, 44(2)：257-260.

[14] Moreno G, Rodríguez A, Sole-Violán J, et al. Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia[J]. ERJ Open Research，2021，7(1)：1-11.

[15] Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial[J].The Lancet Infectious Diseases，2017，17(12): 1255-1265.